疑难病杂志Issue(9)：936-938,943,4.DOI:10.3969/j.issn.1671-6450.2015.09.017
索拉非尼治疗 HBV 相关性肝癌过程中患者血清VEGFR-2及 AFP 水平变化研究
Changes in plasma vascular endothelial growth factor receptor 2 and alpha fetal protein after sorafenib administra-tion for HBV related hepatocellular carcinoma
摘要
Abstract
Objective To investigate the changes of serum of vascular endothelial growth factor receptor 2 ( VEGFR-2) and alpha fetal protein (AFP) levels for using sorafenib in the treatment of HBV related hepatocellular carcinoma (HCC). Methods 46 patients who meet the diagnostic criteria of Barcelona in the late stage of HBV related HCC patients were select-ed and divided into 2 groups, 23 cases in each group , the control group were treated with anti HBV , anti symptomatic , sup-portive and other conventional treatment , the treatment group were treated with sorafenib 400 mg orally on the basis of conven-tional therapy, 2 times a day.6 weeks as 1 observation period.Serum VEGFR-2 and AFP levels were observed in both of the 2 groups.Results Control group’s VEGFR-2’s level in before treatment (8 603.2 pg /ml ±573.4 pg /ml) and after treatment (8 303.1 pg /ml ±527.7 pg /ml) did not show significant changes ( P >0.05); treatment group’s after treat-ment’s level (6 313.8 pg /ml ±559.9 pg /ml) were significantly lower than those before treatment (8 401.1 pg/ml ± 414.6 pg/ml), the difference has statistical significance ( P <0.05).The treatment group’s index was decreased more than that of control group ( P <0.05).The control group and the treatment group ’ s AFP level before treatment were 100.8 (25.0,1 925.1) pg /ml and 89.2 (21.7, 1 567.2) pg /ml, after treatment were 103.7 (18.5.2 083.2) pg/ml and 78.4 (21.6, 684.3) pg/ml, respectively, before and after treatment, AFP had no obvious change in both of the two groups ( P >0.05).VEGFR 2 and AFP level had no correlation( r =-0.337, P =0.048).Conclusion Sorafenib can decrease VEG-FR 2 in patients with HCC , it has certain significance to the clinical treatment of liver cancer .关键词
索拉非尼/HBV/肝癌/VEGFR-2/AFPKey words
Sorafenib/Hepatitis B/Hepatacocellular carcinoma/Vascular endothelial growth factor 2/Alpha fetal protein引用本文复制引用
杨硕,周志平,张云辉,施明,李丰衣,陈威巍..索拉非尼治疗 HBV 相关性肝癌过程中患者血清VEGFR-2及 AFP 水平变化研究[J].疑难病杂志,2015,(9):936-938,943,4.基金项目
国家“十二五”科技重大专项 （）
